Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash from Financing Activities (2016 - 2022)

Historic Cash from Financing Activities for RedHill Biopharma (RDHL) over the last 11 years, with Q2 2022 value amounting to $14.9 million.

  • RedHill Biopharma's Cash from Financing Activities rose 94324.48% to $14.9 million in Q2 2022 from the same period last year, while for Jun 2022 it was $26.5 million, marking a year-over-year decrease of 6542.99%. This contributed to the annual value of $8.4 million for FY2024, which is 6073.98% down from last year.
  • As of Q2 2022, RedHill Biopharma's Cash from Financing Activities stood at $14.9 million, which was up 94324.48% from -$4.9 million recorded in Q1 2022.
  • In the past 5 years, RedHill Biopharma's Cash from Financing Activities registered a high of $59.1 million during Q1 2020, and its lowest value of -$4.9 million during Q1 2022.
  • Its 5-year average for Cash from Financing Activities is $14.4 million, with a median of $7.9 million in 2020.
  • Per our database at Business Quant, RedHill Biopharma's Cash from Financing Activities surged by 7840666.67% in 2018 and then crashed by 13240.52% in 2021.
  • Quarter analysis of 5 years shows RedHill Biopharma's Cash from Financing Activities stood at $18.4 million in 2018, then skyrocketed by 96.67% to $36.1 million in 2019, then plummeted by 78.0% to $7.9 million in 2020, then soared by 121.25% to $17.6 million in 2021, then decreased by 15.11% to $14.9 million in 2022.
  • Its Cash from Financing Activities was $14.9 million in Q2 2022, compared to -$4.9 million in Q1 2022 and $17.6 million in Q4 2021.